Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:33:18 2024-07-05 pm EDT			5-day change	1st Jan Change
27.96 ^USD	+0.96%		+0.09%	-2.73%

05:44pm	Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	MT
05:20pm	UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	MT

PFIZER INC : Credit Suisse gives a Buy rating

January 18, 2023 at 12:14 pm EST

In a research note, Credit Suisse analyst Trung Huynh has maintained his recommendation on the stock with a Buy rating. The target price has been modified and is now set at USD 54 compared to USD 55.

Latest news about Pfizer, Inc.

Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	11:44am	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	11:20am	MT
Pfizer: former State Street CEO joins board	10:14am	CF
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	03:03am	CI
PFIZER INC : Berenberg gives a Neutral rating	Jul. 03	ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	Jul. 03	MT
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount	Jul. 02	MT
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	Jul. 02	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	Jul. 02	MT
Pfizer: new member elected to the Board of Directors	Jul. 02	CF
Vaxcyte Appoints John Furey to Board of Directors	Jul. 02	CI
US DOJ informs Viatris' Mylan is no longer part of antitrust investigation	Jul. 02	RE
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	Jul. 02	MT
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case	Jul. 02	RE
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge	Jul. 01	RE
Vera Therapeutics Appoints David Johnson as Chief Operating Officer	Jul. 01	MT
Pfizer Inc Appoints Cyrus Taraporevala to Board of Directors, Audit Committee and Compensation Committee	Jul. 01	CI
Tiny Chain Bridge is top banker to Trump, Republican campaigns	Jul. 01	RE
Pfizer Inc.(NYSE:PFE) added to Russell 1000 Dynamic Index	Jun. 30	CI
Pfizer: CHMP recommends new Covid vaccine	Jun. 28	CF
Would you like some more inflation?	Jun. 28
EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older	Jun. 28	RE
Pfizer Inc. and BioNTech SE Receives Positive CHMP Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in the European Union	Jun. 28	CI
Pfizer Inc.(NYSE:PFE) dropped from Russell Top 50 Index	Jun. 27	CI
Pfizer, BioNTech Get Positive Committee Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in European Union	Jun. 27	MT

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am EST

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.7 USD

Average target price

31.92 USD

Spread / Average Target

+15.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-2.85%	157B
ELI LILLY AND COMPANY	+56.89%	809B
NOVO NORDISK A/S	+39.52%	624B
JOHNSON & JOHNSON	-6.93%	351B
ABBVIE INC.	+7.48%	289B
ASTRAZENECA PLC	+13.74%	240B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.77%	166B
SANOFI	+1.31%	123B

Other Pharmaceuticals

Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

PFIZER INC : Credit Suisse gives a Buy rating

Latest news about Pfizer, Inc.

Chart Pfizer, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Pfizer, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals